NUKKLEUS INC (NUKK)

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?

CytomX Therapeutics stock is falling hard on Friday as CTMX shareholders appear unimpressed by its latest earnings report.

Why Is ClearOne (CLRO) Stock Up 70% Today?

ClearOne stock is up on Tuesday after the company announced a special one-time cash dividend of 50 cents per share for CLRO holders.

Why Is Nukkleus (NUKK) Stock Up 59% Today?

Nukkleus stock is up on Tuesday alongside heavy pre-market trading of NUKK shares without any clear news from the company.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!

Nukkleus Signs Term Sheet for Acquisition of Leading Cross Border Payments Firm Mercury Global

Goldman Sachs Acquires Stake in Fintech Trailblazer Nukkleus According to a Recent SEC Filing

Nukkleus Appoints C. Derek Campbell to Board of Directors, Bolstering its Growing Footprint in Emerging Markets

Nukkleus partners with Tantel Group to expand footprint in Africa (NASDAQ:NUKK)

Nukkleus Inc and Digital RFQ partner with Tantel Group to expand their presence in the African B2B payments market, aiming to enhance transaction efficiency...

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

Nukkleus Signs MOU to Substantially Increase Holdings in Jacobi Asset Management

Nukkleus Releases Updated Corporate Presentation: Lays Out Vision for Building Financial Infrastructure of the Future

/PRNewswire/ -- Nukkleus Inc. (NASDAQ: NUKK), a pioneering force in the fintech industry, proudly announces its new corporate presentation, marking a...

TUP, POL and WORX among pre-market losers

Losers: Iovance Biotherapeutics (IOVA) -24% announces clinical hold on mid-stage trial for lung cancer therapy.Nukkleus (OTC:NUKK) -23%.Baosheng Media Group...